Das SRL Exhibits New Lab Solutions at MEDLAB 2017
|
By LabMedica International staff writers Posted on 09 Feb 2017 |

Image: The AP22 IF BLOT ELITE system (Photo courtesy of Das SRL).
Das SRL, which designs, manufactures, and markets analyzers and automated equipment for application in immuno-enzimatic, immuno-fluorescence, and clinical chemistry, exhibited its AP22 IF BLOT ELITE system and NEO BIL Plus bilirubinometer at MEDLAB 2017.
Italy-based Das SRL offers systems for automated ELISA process on micro-plates and immunofluorescence on slides; readers and washers for laboratories using micro-titre plates or micro-strips; programmable semi-automated photometers for clinical chemistry analysis; and neonatal bilirubinometers for bilirubin monitoring using centrifuged whole blood samples.
The company’s AP22 IF BLOT ELITE is a fully automated system for ELISA and IFA and BLOT methods. The instrument is capable of running 2 ELISA micro-plates with 8 tests on line, 16 IFA slides or 24 BLOT strips. It can perform full automation for the Dot/Western Blot, from sample dilution and dispensing, reagent dispensing, incubation, and strip washing to dot imaging processing and assessment for each strip.
Also on display at the 4-day exhibition held from February 6-9, 2017, in Dubai, UAE was Das SRL’s NEO BIL Plus, an advanced version of traditional bilirubinometers, designed to analyze the 'total bilirubin' through a microcapillary tube. NEO BIL Plus features a special reading system, which can carry out a precise sample measurement of both bilirubin and interferentials at the same point of the capillary using a small quantity of serum and without any reagents.
Italy-based Das SRL offers systems for automated ELISA process on micro-plates and immunofluorescence on slides; readers and washers for laboratories using micro-titre plates or micro-strips; programmable semi-automated photometers for clinical chemistry analysis; and neonatal bilirubinometers for bilirubin monitoring using centrifuged whole blood samples.
The company’s AP22 IF BLOT ELITE is a fully automated system for ELISA and IFA and BLOT methods. The instrument is capable of running 2 ELISA micro-plates with 8 tests on line, 16 IFA slides or 24 BLOT strips. It can perform full automation for the Dot/Western Blot, from sample dilution and dispensing, reagent dispensing, incubation, and strip washing to dot imaging processing and assessment for each strip.
Also on display at the 4-day exhibition held from February 6-9, 2017, in Dubai, UAE was Das SRL’s NEO BIL Plus, an advanced version of traditional bilirubinometers, designed to analyze the 'total bilirubin' through a microcapillary tube. NEO BIL Plus features a special reading system, which can carry out a precise sample measurement of both bilirubin and interferentials at the same point of the capillary using a small quantity of serum and without any reagents.
Latest MEDLAB 2017 News
- AXA Diagnostics Showcases SkyLAB752 ELISA Analyzer
- Norma Diagnostika Showcases Icon Hematology Analyzers at MEDLAB
- AITbiotech Exhibits abTES Molecular Diagnostics Assays at MEDLAB 2017
- Binding Site Unveils Optilite Protein System
- Priorclave Showcases Energy-Efficient Lab Autoclaves in Dubai
- Diatron Exhibits Abacus 5 and Aquila Hematology Analyzers
- DRG Group Presents New Analyzer and ELISAs at Dubai Lab Exhibition
- Beckman Coulter Exhibits New Lab Solutions in Dubai
- Siemens Healthineers Showcases Latest Diagnostic Innovations
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more









